| Synlogic is a biopharmaceutical company focused on improving its drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer. Co.'s therapeutics programs include: SYNB1020, which is an oral therapy for the treatment of hyperammonemia, including patients with liver disease such as hepatic encephalopathy and patients with urea cycle disorders; and SYNB1618, which is an oral therapy for the treatment of phenylketonuria, a metabolic disease in which the amino acid phenylalanine accumulates in the body as a result of genetic defects. We show 12 historical shares outstanding datapoints in our coverage of SYBX's shares outstanding history.|
Understanding the changing numbers of SYBX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SYBX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SYBX by allowing them to research SYBX shares outstanding history
as well as any other stock in our coverage universe.